AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin

Gemtuzumab ozogamicin (GO), an immunoconjugate between an anti-CD33 antibody and a calicheamicin-γ(1) derivative, induces remissions and improves survival in a subset of patients with acute myeloid leukemia (AML). As the mechanisms underlying GO and calicheamicin-γ(1) resistance are incompletely und...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rosen, David B., Harrington, Kimberly H., Cordeiro, James A., Leung, Ling Y., Putta, Santosh, Lacayo, Norman, Laszlo, George S., Gudgeon, Chelsea J., Hogge, Donna E., Hawtin, Rachael E., Cesano, Alessandra, Walter, Roland B.
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2013
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3539972/
https://ncbi.nlm.nih.gov/pubmed/23320091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0053518
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados